Body SAS Kropsterapi ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  11.6% 15.1% 10.0% 15.0% 9.9%  
Credit score (0-100)  22 13 23 13 19  
Credit rating  B B B B B  
Credit limit (kDKK)  0.0 -0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  159 159 463 409 436  
EBITDA  55.7 -129 146 -22.0 43.0  
EBIT  55.7 -129 146 -22.0 43.0  
Pre-tax profit (PTP)  55.7 -128.3 144.9 -23.5 42.8  
Net earnings  39.5 -128.3 149.0 -12.6 32.6  
Pre-tax profit without non-rec. items  55.7 -128 145 -23.5 42.8  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  89.5 -38.8 110 97.6 130  
Interest-bearing liabilities  14.3 33.6 30.8 8.3 12.7  
Balance sheet total (assets)  171 89.1 192 118 185  

Net Debt  -155 -37.1 -142 -80.0 -142  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  159 159 463 409 436  
Gross profit growth  0.0% -0.4% 191.9% -11.8% 6.7%  
Employees  1 0 1 1 1  
Employee growth %  0.0% -100.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  171 89 192 118 185  
Balance sheet change%  0.0% -47.9% 115.8% -38.5% 56.2%  
Added value  55.7 -129.2 145.9 -22.0 43.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 -1.0 1.0 -1.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  34.9% -81.4% 31.5% -5.4% 9.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  32.6% -86.4% 91.1% -14.1% 28.8%  
ROI %  53.7% -188.1% 167.1% -17.8% 35.0%  
ROE %  44.1% -143.7% 149.5% -12.1% 28.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  52.3% -30.3% 57.3% 82.6% 70.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -277.6% 28.7% -97.7% 364.4% -329.3%  
Gearing %  15.9% -86.6% 28.0% 8.5% 9.8%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% -3.7% 2.9% 7.6% 7.2%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.1 0.7 2.3 5.7 3.4  
Current Ratio  2.1 0.7 2.3 5.7 3.4  
Cash and cash equivalent  168.9 70.7 173.3 88.3 154.5  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  89.5 -38.8 110.2 97.6 130.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  56 0 146 -22 43  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  56 0 146 -22 43  
EBIT / employee  56 0 146 -22 43  
Net earnings / employee  39 0 149 -13 33